Cencora, Inc. reported solid fiscal Q2 2026 results with $78.36 billion in sales but fell short of analyst expectations, prompting a cut in full-year revenue growth guidance from 7%-9% to 4%-6%. Despite this, the company raised its adjusted EPS forecast to between $17.65 and $17.90 and announced plans to repurchase $1 billion in stock by year-end. With $2.2 billion in cash reserves, Cencora aims to bolster shareholder value while focusing on operating income growth in its U.S. Healthcare Solutions segment.
Click a month on the chart to update the report below.